Forzet是一种场外医疗食品,用于防治GLP-1减重药物造成的肌肉损失,可在医生监督下提供。 Wellgistics Health launches Forzet, an over-the-counter medical food to combat muscle loss from GLP-1 weight-loss drugs, available under doctor supervision.

威尔吉斯健康 (WGRX) 推出了ForzetTM,这是一种旨在减少与Ozempic等GLP-1激动剂减肥药物相关的肌肉损失的医疗食品. Wellgistics Health (WGRX) has launched Forzet™, a medical food aimed at reducing muscle loss linked to GLP-1 agonist weight loss drugs like Ozempic. Forzet在柜台上没有处方,打算在医生监督下使用,根据《孤儿药物法》被归类为“特殊医疗目的的食物”。 Available over the counter without a prescription, Forzet is intended for use under physician supervision and is classified as a "food for special medical purposes" under the Orphan Drug Act. 该产品是根据对2型糖尿病、心脏衰竭和脑膜炎综合症患者的临床研究而制成的,是按CGMP标准生产的。 The product, formulated based on clinical studies in patients with Type 2 diabetes, heart failure, and COPD, is manufactured under cGMP standards. 它最初通过 Wellgistics附属药房及其网络提供,并计划将其纳入爱因斯坦罗斯远程保健和药房平台,以便提出销售建议。 It is initially available through Wellgistics-affiliated pharmacies and its network, with plans to integrate it into its EinsteinRx telehealth and pharmacy platform for point-of-sale recommendations. 由于GLP-1治疗部门从2025年的700亿美元扩大至2030年的约2 010亿美元,这一转移旨在应对日益严峻的市场挑战。 The move targets a growing market challenge as the GLP-1 therapy sector expands from $70 billion in 2025 to an estimated $201 billion by 2030.